A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

NCT07529535 · clinicaltrials.gov ↗
PHASE1
Phase
SUSPENDED
Status
16
Enrollment
INDUSTRY
Sponsor class

Stopped Participant recruitment has been stopped because the planned sample size has been reached.

Conditions

Interventions

Sponsor

Zhejiang Anglikang Pharmaceutical Co., Ltd.